BENGALURU (Reuters) – China’s Shanghai Fosun Pharmaceutical Group Co Ltd is considering a sale of Indian drugmaker Gland Pharma Ltd, which has a market value of $3.5 billion, Bloomberg reported, citing people familiar with the matter.
Fosun, which holds a 57.86% stake in Gland Pharma, according to exchange data, did not immediately respond to Reuters’ request for comment. Gland Pharma declined to comment.
(Reporting by Nandan Mandayam in Bengaluru; Editing by Savio D’Souza)
Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibilty for its content.